A study of exercise versus rest in myasthenia gravis

Phase 3

Completed

• Conditions: Myasthenia gravis,

• Registration Number: CTRI/2019/11/021869
• Lead Sponsor: Prinicipal Investigator

Brief Summary

Myasthenia gravis (MG) is a rare autoimmune disease of neuromuscular junction. MG manifests with fatigability and fluctuating weakness of ocular, facial bulbar respiratory, axial and limb muscles.Exercise training is safe nonpharmacological intervention and may have physical and psychological advantages in MG.  There is no randomised controlled trial on the efficacy and safety of exercise in MG .The present study is aimed at evaluating the efficacy and safety of exercise or rest in mild to moderate MG.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-27
• Last Update Posted: 2019-05-11
• Study Completion: 2019-10-20

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• MG patients attending the neurology Outdoor or indoor services of SGPGIMS.
• MGFA score of stage II to III.
• Able to undergo 6minute walk test.

Exclusion Criteria

• Enrolled in another trial.
• Contraindications to exercise like coronary artery disease and stroke and pulmonary disease, osteoarthritis, pregnancy or medical condition reducing survival to less than 2 years.
• Hospitalization in past 8 weeks.
• MGFA score of stage I, IV or V.
• MGQOL score > 45.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
MGQOL-15 score	1,2 and 3 months

Secondary Outcome Measures

Name	Time	Method
1. Increase in the dose of AchEIs drugs or additional immunosuppression or use of PE,IVIG.	2. Myasthenic muscle score: at 1,2 and 3 month.

Trial Locations

Locations (1)

SGPGIMS LUCKNOW; 🇮🇳 Lucknow, UTTAR PRADESH, India

SGPGIMS LUCKNOW

🇮🇳Lucknow, UTTAR PRADESH, India

PROF USHA KANT MISRA

Principal investigator

05222494167

drukmisra@rediffmail.com